Division of Cardiology, Cardiovascular Pulmonary Research Group, School of Medicine, Aurora, CO 80045, USA.
Free Radic Biol Med. 2013 Oct;63:264-73. doi: 10.1016/j.freeradbiomed.2013.05.024. Epub 2013 May 27.
Reactive oxygen species (ROS) formed during acute high altitude exposure contribute to cerebral vascular leak and development of acute mountain sickness (AMS). Nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) is a transcription factor that regulates expression of greater than 90% of antioxidant genes, but prophylactic treatment with Nrf2 activators has not yet been tested as an AMS therapy. We hypothesized that prophylactic activation of the antioxidant genome with Nrf2 activators would attenuate high-altitude-induced ROS formation and cerebral vascular leak and that some drugs currently used to treat AMS symptoms have an additional trait of Nrf2 activation. Drugs commonly used to treat AMS were screened with a luciferase reporter cell system for their effectiveness to activate Nrf2, as well as being tested for their ability to decrease high altitude cerebral vascular leak in vivo. Compounds that showed favorable results for Nrf2 activation from our screen and attenuated high altitude cerebral vascular leak in vivo were further tested in brain microvascular endothelial cells (BMECs) to determine if they attenuated hypoxia-induced ROS production and monolayer permeability. Of nine drugs tested, with the exception of dexamethasone, only drugs that showed the ability to activate Nrf2 (Protandim, methazolamide, nifedipine, amlodipine, ambrisentan, and sitaxentan) decreased high-altitude-induced cerebral vascular leak in vivo. In vitro, Nrf2 activation in BMECs before 24h hypoxia exposure attenuated hypoxic-induced hydrogen peroxide production and permeability. Prophylactic Nrf2 activation is effective at reducing brain vascular leak from acute high altitude exposures. Compared to acetazolamide, methazolamide may offer better protection against AMS. Nifedipine, in addition to its known vasodilatory activities in the lung and protection against high altitude pulmonary edema, may provide protection against brain vascular leak as well.
活性氧 (ROS) 在急性高海拔暴露期间形成,导致脑血管渗漏和急性高原病 (AMS) 的发展。核因子 (红系衍生 2)-相关因子 2 (Nrf2) 是一种转录因子,可调节超过 90%的抗氧化基因的表达,但预防性使用 Nrf2 激活剂作为 AMS 治疗尚未进行测试。我们假设,使用 Nrf2 激活剂预防性激活抗氧化基因组将减轻高空诱导的 ROS 形成和脑血管渗漏,并且一些目前用于治疗 AMS 症状的药物具有额外的 Nrf2 激活特性。我们使用荧光素酶报告细胞系统筛选常用于治疗 AMS 的药物,以确定它们激活 Nrf2 的效果,以及在体内降低高空脑血管渗漏的能力。从我们的筛选中显示出对 Nrf2 激活有利的结果并减轻体内高空脑血管渗漏的化合物在脑微血管内皮细胞 (BMEC) 中进一步进行测试,以确定它们是否减轻缺氧诱导的 ROS 产生和单层通透性。在测试的九种药物中,除了地塞米松外,只有显示出激活 Nrf2 能力的药物(Protandim、甲唑胺、硝苯地平、氨氯地平、安贝生坦和西他生坦)能够减轻体内高空诱导的脑血管渗漏。在体外,在 24 小时缺氧暴露之前在 BMEC 中激活 Nrf2 可减轻缺氧诱导的过氧化氢产生和通透性。预防性 Nrf2 激活可有效减少急性高空暴露引起的脑血管渗漏。与乙酰唑胺相比,甲唑胺可能对 AMS 提供更好的保护。除了在肺部的已知血管扩张作用和对高原肺水肿的保护作用外,硝苯地平也可能对脑血管渗漏提供保护作用。